

In re: Gallagher et al.
Serial No.: 10/572,870
Filed: May 9, 2007
Page 2 of 2

REMARKS

Claims 1-90 are pending in the present application. In the Office Action, the Examiner restricted the claims into nine groups. Applicants hereby elect Group 1, claims 1-82. This election is with traverse only to the extent that Applicants believe claim 83 should be grouped with Group 1 rather than with Groups 4-6. Claim 83 is directed to the pharmaceutical composition of claim 82 wherein the compound is present in an amount effective to inhibit the growth of multidrug resistant cells. As the composition of claim 83 does not comprise an additional active ingredient, it is more appropriately placed with claims 1-82 in Group 1.

Applicants respectfully submit that this application is in condition for substantive examination, which action is respectfully requested. The Examiner is also encouraged to contact the undersigned directly at (919) 854-1400, if such contact will expedite the examination and allowance of the pending claims.

Respectfully submitted,




Robert A. Schwartzman, Ph.D.
Registration No. 50,211
Attorney for Applicants

USPTO Customer No. 20792
Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428, Raleigh, NC 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401

CERTIFICATION OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4) to the U.S. Patent and Trademark Office on February 17, 2009.

Signature: 
Marthen Salazar